Mesenchymal Stem Cell Fates in Murine Acute Liver Injury and Chronic Liver Fibrosis Induced by Carbon Tetrachloride

Chenhui Ma, Li Han, Jiajun Wu, Feng Tang, Qiangqiang Deng, Ting He, Zhitao Wu, Chen Ma, Wei Huang, Ruimin Huang, and Guoyu Pan

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (C.M., L.H., J.W., F.T., Q.D., T.H., Z.W., C.M., W.H., R.H., G.P.); University of Chinese Academy of Sciences, Beijing, China (C.M., L.H., J.W., F.T., C.M., W.H., R.H., G.P.); and School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China (T.H.)

Received May 28, 2022; accepted July 7, 2022

ABSTRACT

Mesenchymal stem cells (MSCs) therapy has shown potential benefits in multiple diseases. However, their clinic performance is not as satisfactory as expected. This study aimed to provide an alternative explanation by comparing MSCs’ fates in different liver diseases. The distribution and therapeutic effects of human MSC (hMSCs) were investigated in acute liver injury (ALI) and chronic liver fibrosis (CLF) mice models, respectively. The two models were induced by single or repeated injection of carbon tetrachloride separately. The increase of hMSCs exposure in the liver (AUC_{liver }0–72 h) were more significant in ALI than in CLF (177.1% versus 96.2%). In the ALI model, the hMSCs exposures in the lung (AUC_{lung} 0–72 h) increased by nearly 50%, whereas it decreased by 60.7% in CLF. The efficacy satellite study indicated that hMSCs could significantly ameliorate liver injury in ALI, but its effects in CLF were limited. In the ALI, suppressed natural killer (NK) cell activities were observed, while NK cell activities were increased in CLF. The depletion of NK cells could increase hMSCs exposure in mice. For mice MSC (mMSCs), their cell fates in ALI were very similar to hMSCs in ALI: mMSCs’ exposure in the liver and lung increased in ALI. In conclusion, our study revealed the distinct cell pharmacokinetic patterns of MSC in ALI and CLF mice, which might be at least partially attributed to the different NK cell activities in the two liver diseases. This finding provided a novel insight into the varied MSCs’ therapeutic efficacy in the clinic.

SIGNIFICANCE STATEMENT

Currently, there is little knowledge about the PK behavior of cell products like MSCs. This study was the first time investigating the influence of liver diseases on cell fates and efficacies of MSCs and the underneath rationale. The exposure was distinct between two representative liver disease models, which directly linked with the therapeutic performance that MSCs achieved. The difference could be attributed to the NK cells–mediated MSCs clearance.

Introduction

Mesenchymal stem cells (MSCs) have already exhibited great potency in multiple diseases. For example, MSCs exerted beneficial effects against graft-versus-host disease and were recommended as a second-line treatment option for acute graft-versus-host disease (Zhao et al., 2022). Besides, the survival rate of patients with hepatitis B-associated liver failure was significantly improved by human MSCs (hMSCs) (79.2%) compared with the control group (52.6%) during the first 12 weeks of follow up (Shi et al., 2012).

However, there are plenty of contrasting reports about the clinical performance of MSCs, and the results are not as satisfactory as what has been achieved in preclinical animal studies (Daley, 2012; Xu et al., 2018). Many clinical trials found a substantial nonresponse rate and significant individual variabilities after MSCs treatment (Wysocky et al., 2018; Zhao et al., 2018). For example, one study reported an improved survival rate and liver function after MSCs treatment in acute-on-chronic liver failure patients (Shi et al., 2012). In contrast, another study showed that MSCs couldn’t benefit decompensated cirrhosis patients (Mohamadnejad et al., 2013). The inconsistency may be partly explained by the varied resources and derivation, the CMC quality, and clinical delivery routes. However, the variance of patients' immune systems and disease severity is a crucial but less recognized source of heterogeneity in cell therapy (Yang et al., 2020).

Previous studies indicated that most MSCs mainly distributed in the lung and liver and have limited engraftment capacity (Shim et al., 2015; Creane et al., 2017). However, whether the pharmacokinetic (PK) pattern of MSCs would be altered under diseases and the mechanism remains to be elucidated. Natural killer (NK) cells are innate immune cells endowed with the inherent ability to recognize and eliminate foreign and infected cells (Freud et al., 2017). Although activated natural killer cells were reported to facilitate MSCs lysis in vitro (Poggi et al., 2005), to our knowledge, there is no direct evidence linking NK cell function with MSCs therapeutic efficacy and disposition during liver diseases.

Given the efficacy instability and discrepancy observed among MSCs-related studies, our work aimed to find potential explanations by

ABBREVIATIONS: ALI, acute liver injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl4, carbon tetrachloride; CLF, chronic liver fibrosis; FU, fluorescent units; IVIS, in vivo imaging system; MSC, mesenchymal stem cell; NK, natural killer cells; PK, pharmacokinetics; qPCR, quantitative polymerase chain reaction.
investigating the fate of MSCs in two representative liver injury mice models: carbon tetrachloride (CCl\textsubscript{4})-induced acute liver injury (ALI) and CCl\textsubscript{4}-induced chronic liver fibrosis (CLF). The PK behavior, the therapeutic performance, the role of NK cells-mediated clearance, and species difference would be systemically compared to explore the potential regulator of the pharmacokinetics (PK) and pharmacodynamics patterns of MSCs, a promising cell-based therapy.

Materials and Methods

Cells. The human umbilical cord-derived mesenchymal stem cells (hMSCs) were kindly provided by Hexaell Biotech (Shanghai, China). The umbilical cord was collected from the informed consent mother, according to a protocol approved by the Institutional Ethical Review Committee of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University. MSCs were isolated according to a previous study (Han et al., 2013; Zhong et al., 2020). Briefly, umbilical cord tissues were digested and digested with collagenase IV (Sigma, St. Louis, MO) and Trypsin (Gibco, Carlsbad, CA). The cell pellet was then resuspended and cultured, hMSCs were further expanded by changing the medium every two days. The culture medium was a minimal essential medium (MEM, Gibco) with 10% fetal bovine serum (FBS) (Sigma) and 1% penicillin-streptomycin (P/S) (Gibco). The mice adipose-derived mesenchymal stem cells (mMSCs) were isolated from male Balb/c mice, as reported previously (Estes et al., 2010). mMSCs were cultured in Dulbecco’s modified Eagle’s medium (Hyclone, Logan, UT) with 10% FBS and 1% penicillin-streptomycin and 1% P/S. The hMSCs used in subsequent experiments were between passages three to seven. The mMSCs were used at passage two or three. The human cell line NK2 was obtained from the American Type Culture Collection (ATCC). NK2 cells were cultured in MEM (Gibco) supplemented with 25% FBS, 0.2 M inositol (Sigma), 0.1 M 2-mercaptoethanol (Sigma), 0.02 M folic acid (Sigma), and 100 U ml\textsuperscript{-1} recombinant human IL-2 (Peprotech, Rocky Hill, NJ). All cells were cultured in a humidified 5% CO\textsubscript{2}, 95% air incubator at 37°C.

Fluorescent Labeling to Detect the Biodistribution of MSCs. The in vivo distribution of injected hMSCs was monitored according to our previous paper (Han et al., 2021). Briefly, hMSCs were harvested with 0.25% Trypsin (Gibco) and washed by PBS three times. Then, cell pellet was incubated with 10 μM Cy5-NHS (Meilunbio, China) in PBS (pH 8.0) at 37°C for 30 minutes. The reaction was terminated by adding 100 mM glycine and then washed with PBS three times. The pellet was then resuspended in a sterile PBS and subjected to intravenous injection. Mice were treated with 200 μl labeled hMSCs or mMSCs (5 x 10\textsuperscript{5} cells per mice). Mice were anesthetized with pentobarbital (50 mg kg\textsuperscript{-1} i.p.) and sacrificed. Organs (heart, liver, spleen, lung, and kidney) were collected and washed with sterile normal saline. The fluorescence of labeled MSCs in tissues was detected in an in vivo imaging system (IVIS) (PerkinElmer, Waltham, MA) with a fixed exposure time (1 second) and filter setting of 640 nm excitation and 680 nm emission. Imaging analysis was performed using Living Image software (Caliper, Waltham, MA) to obtain the average radiance of each tissue. Fluorescent units (FU) were used to obtain the Fluorescence-intensities-Time curve and PK parameters (see “Statistical Analysis”).

Detection of Human-Derived MSCs by Quantitative Real-Time PCR (qPCR). About 10 mg of tissues were weighted for gDNA isolation using genomic DNA extraction kits (Magen, China). Quantitative real-time PCR (qPCR) was performed in a 20 μl total reaction volume containing 10 μl SYBR Green master mix (Yasoon biotech, Shanghai, China), 200 ng of gDNA, and 1 μl forward and reverse primers in a 7500 Real-Time PCR system (ABI, Foster City, CA). The human-specific Alu primer and β-actin were listed in Supplementary Table 1. hMSCs amounts in mice tissues were calculated according to the standard curve based on the logarithm of cell number and the CT value, according to our previous paper (Han et al., 2021).

Animals. All animal experiments were performed following the Ethical Treatment of Laboratory guidelines. The protocols involving animal experiments were reviewed and approved by the Institute of Animal Care and Use Committee of the Shanghai Institute of Medical Science, Chinese Academy of Sciences. Male Balb/c mice (6–8 weeks) were purchased from the Shanghai SLAC Laboratory Animal Co. (Shanghai, China). All animals were maintained under the Specific-pathogen-free (SPF) condition with a constant temperature (23 ± 1.5°C) and humidity (55 ± 5%) on a 12-hour light and dark cycle.

CCl\textsubscript{4}-Induced Acute Liver Failure (ALI) in Mice. To determine the efficacy and pharmacokinetics of MSCs in acute liver disease, the conventional CCl\textsubscript{4}-induced ALI were employed. Balb/c mice were randomly divided into the following four groups (n = 4–5): control, hMSC, ALI, and hMSCs + ALI (Fig. 1A). The mice in the liver failure groups were intraperitoneally administered with 5 ml kg\textsuperscript{-1} of CCl\textsubscript{4} (Sinopharm, China) dissolved in olive oil (v/v, 20%, Sinopharm, China), whereas normal mice received solvent only as control. 6 hours after CCl\textsubscript{4} injection, 5 x 10\textsuperscript{5} labeled MSCs diluted in 200 μl PBS on the equal volume of PBS were administered to mice via tail vein. Tissues were collected and imaged at 1, 8, 24, 48, and 72 hours after MSCs treatment to detect the biodistribution using IVIS. Liver, lung, and blood samples were also collected at 72 hours for histologic and biochemical analysis.

CCl\textsubscript{4}-Induced Chronic Liver Fibrosis (CLF) in Mice. To investigate the potential different pharmacokinetic properties of MSCs in acute and chronic liver diseases, multiple doses of CCl\textsubscript{4} were administrated to induce liver fibrosis (Fig. 1E). Briefly, mice were randomly divided into four groups: control, hMSCs, fibrosis, and hMSCs + fibrosis. Mice received 20% CCl\textsubscript{4} (dissolved in olive oil, 5 ml kg\textsuperscript{-1}, i.p.) or vehicle twice a week as previous described (Ye et al., 2019).

To evaluate the protective effect against fibrosis, hMSCs (5 x 10\textsuperscript{5} cells per mice) or PBS were injected into mice (n = 3–4) at 6 hours after the final administration of CCl\textsubscript{4} on the sixth week of the fibrosis model. 72 hours after hMSCs transplantation, mice were anesthetized and sacrificed, and serum, liver, and lung samples were harvested and maintained for further analysis.

To examine the biodistribution in advanced fibrosis, remaining mice (n = 5) received hMSCs (5 x 10\textsuperscript{5} cells per mice, i.v.) or PBS after the last CCl\textsubscript{4} injection on the eighth week. Mice were sacrificed and tissue samples were collected for IVIS examination at 1, 8, 24, 48, and 72 hours after hMSCs administration.

NK Depletion in Mice. To validate the role of NK cells in the elimination of MSCs, the NK cells were temporarily depleted in vivo by intraperitoneal injection of 25 μl anti-asialo GM-1 antibody (Biotrend, San Diego, CA) 48 hours before the hMSCs administration. Then, the fluorescence intensities in tissues were detected at 1, 8, 24, 48, and 48 hours using the IVIS system.

Immunohistochemistry. Mouse liver and lung fixed with 4% paraformaldehyde were embedded in paraffin. 4 μm section tissues were sliced, followed by hematoxylin and eosin (H and E), according to standard protocol. Images of stained slides were visualized and captured by NanoZoomer S210 (Hamamatsu, Japan). For liver fibrosis analysis, 4-μm-thick liver sections were stained with Sirius red for collagen deposition and immunohistochemical staining for α-smooth muscle actin (α-SMA) (Abcam, Cambridge, MA). ImageJ Fiji (Schindelin et al., 2012) software was used to assess the area positive stained for Sirius-red staining and α-SMA protein expression at ≥20 magnification. The area percentage from five randomly selected fields were counted and subjected to further statistical analysis.

Biochemical Analysis. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using commercial kits following the manufacturer’s instructions (Nanjing JianCheng, China).

Western Blot. Protein samples were extracted from about 10 mg of frozen liver or lung by incubating with RIPA lysis buffer (Beyotime, China) supplemented with 1% proteinase cocktail (Sigma) on ice. Protein quantification was performed by the BCA Protein Assay Kit (Beyotime, China). Protein samples in sodium dodecyl sulfate (SDS, Meilunbio) buffer was heated to 95°C for 10 minutes and separated on SDS-polyacrylamide gels. Resolved proteins were then transferred onto PVDF (Polyvinylidene fluoride) membranes (Millipore, USA) and blocked with 5% milk in TBST (Tween-TBS buffer). The respective samples were blotted with antibodies overnight at 4°C against primary antibodies: anticollegen 1a1 polyclonal antibody (1:1000, Proteintech, Chicago, IL), anti-α-SMA polyclonal antibody (1:1000, Proteintech) and anti-GAPDH polyclonal antibody (1:1000, Proteintech). Membranes were washed three times and then incubated for 1 hour at room temperature with HRP-conjugated anti-rabbit IgG (1:5000, Yeason biotech) and visualized by Pierce ECL Western Blotting Substrate (Thermo Fisher, Waltham, MA) in the CLINX ChemiScope 3500 mini system (Shanghai, China). The intensity of each band was determined using ImageJ software (National Institutes of Health, Bethesda, MD).

RNA Extraction and qPCR Analysis. Total RNA was extracted from about 10 mg of liver or lung using TRIzol reagent (Life Technology, Waltham, MA). Total RNA was reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland) according to the manufacturer’s instructions. qPCR was performed in a 20 μl total reaction volume containing 10 μl LightCycler 480 SYBR Green Master Mix (Roche). The following primer sets were used: 18S for normalized expression analysis, and inflammatory related genes, namely COL1A1, IL-10, IL-6, TNF-α, and IL-1β, for the analysis of inflammation.

Statistical Analysis. The statistical analysis was performed using GraphPad Prism 8 (San Diego, CA). The data were presented as mean ± standard deviation (SD) or mean ± standard error of the mean (SEM). The significance of differences between the two groups was determined by an unpaired t-test. For multiple comparisons, one-way ANOVA followed by a Tukey’s post-hoc test was used. A p-value < 0.05 was considered statistically significant. This study was conducted following the guidelines of the ARRIVE (Animal Research: Reporting in vivo Experiments) guidelines. All experiments were performed at least in triplicate.
MA) and UNIQ-10 RNA RN column and collection tubes (Sangon Biotech, China). 1 ug of total RNA was used as a template for reverse transcription with 5xRT Master Mix (Takara, Japan), followed by qPCR detection with SYBR Green and primers as described above. Relative mRNA expression was normalized to the level of GAPDH and calculated using the 2-ΔΔCT method. Primers were designed and listed as shown in Supplement Table1.

Flow Cytometry. The cell suspension was prepared by the digestion of fresh tissues (~30 mg of liver, ~10 mg of lung or spleens) in 1.5 mg·ml⁻¹ Collagenase Type I (to digest lung, Sigma) or Type IV (to digest liver and spleen, Sigma) dissolved in Roswell Park Memorial Institute 1640 medium (RPMI 1640, Meilunbio) at 37°C, 200 rpm for 1 hour. Single cells were then obtained by filtering and removing red blood cells by a Red Blood lysis buffer (Beyotime, China). Lymphocytes in blood were isolated using the Lymphocyte separation kit (Dakewe, China). The proportion of CD49b⁺ cells in liver and lung treated with hMSCs. (I) Gross examination showed enlargements of the liver, lung, and spleen in mice from the CLF model. Relative α-SMA protein expression in the liver and lung from the CLF model were detected by western blot. Data are shown as the mean ± S.D. (n = 3–5, *P < 0.05, **P < 0.01, versus Control (Pos) or 20 μl medium to the test wells and incubated at 37°C for 4 hours. The LDH release was performed as the instruction mentioned (Dojinjo, Japan). After incubation, 20 μl of lysis buffer was added to the Positive Control (Pos) wells or 20 μl medium to the test wells and incubated at 37°C for 4 hours. The plate was centrifuged at 250 × g for 2 minutes and 100 μl of supernatant was transferred to a new 96-well plate. The reaction was induced by adding a working solution and stopped by a stop solution. The absorbance was measured at 490 nm by a microplate reader (BioTek, Winooski, VT). Cell cytotoxicity% was calculated according to the manufacturer’s protocol, whereas the cytotoxicity% of the Pos group was set at 100%.

Statistical Analysis. All data were analyzed by GraphPad Prism software (version 8.0, GraphPad software, San Diego, CA) via one-way or two-way ANOVA, followed by Tukey’s post hoc test for multiple comparisons between groups. The data are expressed as the mean ± S.D. *P < 0.05 was considered statistically significant. The pharmacokinetic parameters were calculated by non-compartmental analysis with WinNonlin software (version 6.2; Pharsight, NC). The peak concentration (Cmax), the peak time (Tmax), the area under the concentration-time curve (AUC), elimination half-life(t1/2), and mean residence time (MRT) were determined separately.

Results

hMSCs Significantly Ameliorated Liver Inflammation in CCl₄-Induced Acute Liver Injury but Had Limited Effects against CCl₄-Induced Chronic Liver Fibrosis. In this study, two representative liver disease models, acute liver injury (ALI), and chronic liver fibrosis (CLF) were induced respectively and the therapeutic performance of hMSCs achieved in the two disease models were comprehensively investigated.
In the ALI experiment, a single dose of CCl4 was intraperitoneally injected into Balb/c mice at 6 hours before labeled hMSCs or mMSCs (5 × 10^5 cells per animal) transplantation (Fig. 1A). The elevated serum ALT/AST levels were significantly lowered in both hMSCs and mMSCs groups (Fig. 1B). mMSCs treatment worked better in ameliorating the increased proinflammatory genes (TNF-α, IL-1β, and MCP-1) expression in the mice liver (Fig. 1C). Typical histopathological patterns of ALI were also observed in the injured liver, including severe hepatic necrosis, inflammatory cell infiltration, and hemorrhage (Fig. 2A). Hepatic necrosis and inflammation were improved on day 3 after MSCs administration. No significant histologic changes were observed in the murine lung after receiving MSC treatment (Fig. 2B, C). After hMSC treatment, hepatic histologic examination showed some extent of improvement, but the data were not statistically significant (Fig. 2, B and C).

Gross examination showed enlargements of the liver, lung, and spleen, rougher and harder liver, and obvious pulmonary congestion in fibrosis mice (Fig. 1I). hMSCs could reduce serum ALT/AST levels and hepatic profibrotic gene and α-SMA protein expressions (Fig. 1, F–G, L, and J). H and E, Sirius red staining (for collagen), and α-SMA (biomarker of myofibroblast) expression all indicated that collagen deposition and inflammatory cell infiltration occurred in the fibrotic liver (Fig. 2, B and C).

According to previous studies, chronic interstitial pneumonia and intra-alveolar fibrosis could be observed during long-term administration of CCl4 (Paakko et al., 1996; Taslidere et al., 2014). The pathology of lung tissues was also investigated. The increased expression of Col3a1 and TNF-α genes and α-SMA were observed in fibrosis mice (Fig. 1, H and K). The results suggested a single hMSCs injection could not reverse the pathologic damage in the lung in CLF animals (Fig. 2B), but it may improve the animal condition and delay fibrosis development.
The Cmax and AUClung 0–72 hour decreased significantly (Table 1). Surprisingly, after a single administration of hMSCs, AUCliver 0–72 hour increased by 96.2% in the CLF, whereas the AUCliver 0–72 hour increased by 177.1% in the ALI mice (Tables 1 and 2).

hMSCs Exposure Was Increased in the Lung of ALI Mice, Whereas Decreased in CLF. The divergent improvement of cell exposure in the lung could not fully explain the efficacy difference of hMSCs. Since the lung is the major site for MSC distribution and elimination, the change of MSC exposure in the lung was further investigated. In ALI mice, more injected MSC cells accumulated in the lung compared with healthy animals (Fig. 3A and Supplemental Fig. 2A). The Cmax and AUClung 0–72 hour increased by 50.5% and 51.1%, respectively (Table 1). Surprisingly, after a single administration of hMSCs, hMSCs accumulation in the lung decreased significantly in CLF animals (Fig. 3D and Supplemental Fig. 2C). The Cmax and AUClung 0–72 hour were reduced by nearly 57.5% and 60.7%, respectively (Table 2).

Since the majority of MSC injected was accumulated in the lung, not the liver (AUClung 0–72 hour was near 10-folds the value of AUCliver 0–72 hour), the overall reduced residence time of hMSCs in the lung of CLF was consistent with its limited efficacy after a single administration.

NK Cells Were Downregulated in ALI but Activated in CLF. To find out the reason behind the divergent performance against liver injury in two liver injury models, we first compared the distribution of hMSCs (Supplemental Fig. 1, A and B). The fluorescent intensity of hMSCs in the ALI and CLF mice liver was increased significantly (Fig. 3, A and B). The result was confirmed by qPCR (Supplemental Fig. 2, B and D). The results indicated that the residence time of hMSC in the liver (MRT) was both extended significantly. The AUCliver 0–72 hour was increased by 96.2% in the CLF, whereas the AUCliver 0–72 hour increased by 177.1% in the ALI mice (Tables 1 and 2).

hMSCs Exposure Was Increased in the Lung of ALI Mice, Whereas Decreased in CLF. The divergent improvement of cell exposure in the lung could not fully explain the efficacy difference of hMSCs. Since the lung is the major site for MSC distribution and elimination, the change of MSC exposure in the lung was further investigated. In ALI mice, more injected MSC cells accumulated in the lung compared with healthy animals (Fig. 3C and Supplemental Fig. 2A). The Cmax and AUClung 0–72 hour increased by 50.5% and 51.1%, respectively (Table 1). Surprisingly, after a single administration of hMSCs, hMSCs accumulation in the lung decreased significantly in CLF animals (Fig. 3D and Supplemental Fig. 2C). The Cmax and AUClung 0–72 hour were reduced by nearly 57.5% and 60.7%, respectively (Table 2).

Since the majority of MSC injected was accumulated in the lung, not the liver (AUClung 0–72 hour was near 10-folds the value of AUCliver 0–72 hour), the overall reduced residence time of hMSCs in the lung of CLF was consistent with its limited efficacy after a single administration.

NK Cells Were Downregulated in ALI but Activated in CLF. To find out the reason behind the divergent performance against liver injury in two liver injury models, we first compared the distribution of hMSCs (Supplemental Fig. 1, A and B). The fluorescent intensity of hMSCs in the ALI and CLF mice liver was increased significantly (Fig. 3, A and B). The result was confirmed by qPCR (Supplemental Fig. 2, B and D). The results indicated that the residence time of hMSC in the liver (MRT) was both extended significantly. The AUCliver 0–72 hour was increased by 96.2% in the CLF, whereas the AUCliver 0–72 hour increased by 177.1% in the ALI mice (Tables 1 and 2).

Since the majority of MSC injected was accumulated in the lung, not the liver (AUClung 0–72 hour was near 10-folds the value of AUCliver 0–72 hour), the overall reduced residence time of hMSCs in the lung of CLF was consistent with its limited efficacy after a single administration.

NK Cells Were Downregulated in ALI but Activated in CLF. To find out the reason behind the divergent performance against liver injury in two liver injury models, we first compared the distribution of hMSCs (Supplemental Fig. 1, A and B). The fluorescent intensity of hMSCs in the ALI and CLF mice liver was increased significantly (Fig. 3, A and B). The result was confirmed by qPCR (Supplemental Fig. 2, B and D). The results indicated that the residence time of hMSC in the liver (MRT) was both extended significantly. The AUCliver 0–72 hour was increased by 96.2% in the CLF, whereas the AUCliver 0–72 hour increased by 177.1% in the ALI mice (Tables 1 and 2).

The divergent improvement of cell exposure in the lung could not fully explain the efficacy difference of hMSCs. Since the lung is the major site for MSC distribution and elimination, the change of MSC exposure in the lung was further investigated. In ALI mice, more injected MSC cells accumulated in the lung compared with healthy animals (Fig. 3C and Supplemental Fig. 2A). The Cmax and AUClung 0–72 hour increased by 50.5% and 51.1%, respectively (Table 1). Surprisingly, after a single administration of hMSCs, hMSCs accumulation in the lung decreased significantly in CLF animals (Fig. 3D and Supplemental Fig. 2C). The Cmax and AUClung 0–72 hour were reduced by nearly 57.5% and 60.7%, respectively (Table 2).

Since the majority of MSC injected was accumulated in the lung, not the liver (AUClung 0–72 hour was near 10-folds the value of AUCliver 0–72 hour), the overall reduced residence time of hMSCs in the lung of CLF was consistent with its limited efficacy after a single administration.

NK Cells Were Downregulated in ALI but Activated in CLF. To find out the reason behind the divergent performance against liver injury in two liver injury models, we first compared the distribution of hMSCs (Supplemental Fig. 1, A and B). The fluorescent intensity of hMSCs in the ALI and CLF mice liver was increased significantly (Fig. 3, A and B). The result was confirmed by qPCR (Supplemental Fig. 2, B and D). The results indicated that the residence time of hMSC in the liver (MRT) was both extended significantly. The AUCliver 0–72 hour was increased by 96.2% in the CLF, whereas the AUCliver 0–72 hour increased by 177.1% in the ALI mice (Tables 1 and 2).

The divergent improvement of cell exposure in the lung could not fully explain the efficacy difference of hMSCs. Since the lung is the major site for MSC distribution and elimination, the change of MSC exposure in the lung was further investigated. In ALI mice, more injected MSC cells accumulated in the lung compared with healthy animals (Fig. 3C and Supplemental Fig. 2A). The Cmax and AUClung 0–72 hour increased by 50.5% and 51.1%, respectively (Table 1). Surprisingly, after a single administration of hMSCs, hMSCs accumulation in the lung decreased significantly in CLF animals (Fig. 3D and Supplemental Fig. 2C). The Cmax and AUClung 0–72 hour were reduced by nearly 57.5% and 60.7%, respectively (Table 2).

Since the majority of MSC injected was accumulated in the lung, not the liver (AUClung 0–72 hour was near 10-folds the value of AUCliver 0–72 hour), the overall reduced residence time of hMSCs in the lung of CLF was consistent with its limited efficacy after a single administration.
However, when we explored the CCl4-induced ALI model is applied to reproduce acute liver injury or inflammation response, and attract transplanted MSCs into the injury sites (Leibacher and Henschler, 2016). Actually, it has been confirmed in previous reports that usually at least two repeated administrations of MSCs were required to attenuate liver fibrosis in CLF models (Ali et al., 2012; Luo et al., 2019). For example, the dosage regimen in one successful MSCs' treatment on decompensated liver cirrhosis required patients to receive MSCs transfusion once every 4 weeks three times (8 weeks in total) (Zhang et al., 2012).

**PK Pattern of mMSCs in ALI was Comparable to hMSCs.** The exposure of mouse-derived MSCs were investigated in ALI animals. The mouse adipose-tissue derived MSCs were employed as research control to identify potential species difference.

The result indicated that mMSCs residence in the lung and liver was also significantly increased during ALF (Fig. 6, A and B). NK cells in the lung and liver were also remarkably decreased (Fig. 6, C and D). Those data implied that mMSCs cell fate was close to human-derived MSCs in the CCL4-induced liver injury model (Fig. 3, A and C).

**Discussion**

Mesenchymal stem cells have been widely investigated in diseases at preclinical studies. However, in a lot of scenarios, MSCs failed to show expected results in clinical trials (Galipeau and Sensebe, 2018). The main aim of this study was to supply an alternative explanation from the pharmacokinetic perspective. CCL4 is a classic toxin, which could induce hepatic oxidative stress, inflammation response, and fibrosis (Weber et al., 2003; Torres et al., 2016; Zhang et al., 2017). CCL4-induced ALI model is applied to reproduce acute liver injury or fulminant liver failure, whereas the CLF model could mimic human chronic liver fibrosis and cirrhosis. In this study, the ALI and CLF model were established by the same dose of CCL4 with different administration frequencies. The purpose is to minimize the disturbances of potential variables, such as chemical agents, animal strains, and others (Liu et al., 2019; Ye et al., 2019). We have observed the homing of MSC in the liver of both models (the exposure of hMSCs in the liver of two models was significantly enhanced), consistent with previous literature (Karp and Leng Teo, 2009). However, when we explored the cell fate in tissues beyond the liver, a distinct difference in hMSCs exposure in the lung was noticed between ALI and CLF animals. The activation or suppression of NK cells in different liver injury models might contribute to this distribution pattern of MSCs. The results indicate the exposure correlated with the extent of MSC hepatoprotective performance in the two models.

We wonder whether a single administration of hMSCs was able to protect the liver from inflammation in two representative models. In ALI mice, hMSCs significantly reduced the ALT and AST levels and the proinflammation gene expressions (Fig. 1, B and C), consistent with reported studies before (Shi et al., 2019). Whereas in CLF, although single hMSCs administration reduced ALT/AST levels, it showed limited efficacy against chronic hepatic and pulmonary fibrosis (Fig. 1, G and H; Fig. 2, B and C). Actually, it has been confirmed in previous reports that usually at least two repeated administrations of MSCs were required to attenuate liver fibrosis in CLF models (Ali et al., 2012; Luo et al., 2019). For example, the dosage regimen in one successful MSCs' treatment on decompensated liver cirrhosis required patients to receive MSCs transfusion once every 4 weeks three times (8 weeks in total) (Zhang et al., 2012).

The exposure of hMSCs in the liver of these two models was both significantly enhanced, but hMSCs had a greater increase in the AUC_{Lung} 0–72 hour in ALI than CLF (177% versus 96.2%). The AUC_{Liver} 0–72 hour of hMSCs also increased significantly in ALI lung (51.1%). However, in CLF mice, a surprisingly declined hMSCs exposure was noticed: the AUC_{Lung} 0–72 hour and C_{max} decreased by 60.7% and 57.5%, respectively (Table 2). The PK properties showed similar trends in the fluorescent detection and qPCR assays (Fig. 3 and Supplemental Fig. 2).

Therefore, the next question is why MSCs had opposite cell fates in the lung of ALI and CLF. It has been widely reported that MSCs possess a homing capacity. The inflammatory sites would release signals and attract transplanted MSCs into the injury sites (Leibacher and Henschler, 2016). In our CLF model, pulmonary pathology, like inflammation infiltration, alveolar fibrosis, and stale hemorrhage, were all observed (Fig. 2B). However, the accumulation of MSCs in the lung significantly decreased compared with the control (Fig. 3D). This phenomenon couldn't be explained by the cell homing theory.

**TABLE 1**

<table>
<thead>
<tr>
<th>Liver</th>
<th>T_{max} (h)</th>
<th>MRT (h)</th>
<th>t_{1/2} (h)</th>
<th>C_{max} (FU × 10^5)</th>
<th>AUC_{0–72 h} (FU × h × 10^5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hMSCs</td>
<td>1</td>
<td>18.7 ± 0.9</td>
<td>27.5 ± 2.6</td>
<td>136.8 ± 7.8</td>
<td>2125.0 ± 83.1</td>
</tr>
<tr>
<td>+ ALI</td>
<td>1</td>
<td>24.9 ± 3.4*</td>
<td>22.4 ± 4.9</td>
<td>147.6 ± 31.3</td>
<td>58890.0 ± 580.9***</td>
</tr>
<tr>
<td>Lung</td>
<td>24</td>
<td>30.9 ± 1.1</td>
<td>28.0 ± 4.2</td>
<td>418.5 ± 56.4</td>
<td>20588.0 ± 1068.0</td>
</tr>
<tr>
<td>hMSCs</td>
<td>24</td>
<td>33.0 ± 4.7</td>
<td>41.6 ± 7.3**</td>
<td>629.8 ± 43.9***</td>
<td>31100.0 ± 1450.0***</td>
</tr>
</tbody>
</table>

*P < 0.05, **P < 0.01, ***P < 0.001, versus hMSCs.

**Discussion**

Mesenchymal stem cells have been widely investigated in diseases at preclinical studies. However, in a lot of scenarios, MSCs failed to show expected results in clinical trials (Galipeau and Sensebe, 2018). The main aim of this study was to supply an alternative explanation from the pharmacokinetic perspective. CCL4 is a classic toxin, which could induce hepatic oxidative stress, inflammation response, and fibrosis (Weber et al., 2003; Torres et al., 2016; Zhang et al., 2017). CCL4-induced ALI model is applied to reproduce acute liver injury or fulminant liver failure, whereas the CLF model could mimic human chronic liver fibrosis and cirrhosis. In this study, the ALI and CLF model were established by the same dose of CCL4 with different administration frequencies. The purpose is to minimize the disturbances of potential variables, such as chemical agents, animal strains, and others (Liu et al., 2019; Ye et al., 2019). We have observed the homing of MSC in the liver of both models (the exposure of hMSCs in the liver of two models was significantly enhanced), consistent with previous literature (Karp and Leng Teo, 2009). However, when we explored the cell fate in tissues beyond the liver, a distinct difference in hMSCs exposure in the lung was noticed between ALI and CLF animals. The activation or suppression of NK cells in different liver injury models might contribute to this distribution pattern of MSCs. The results indicate the exposure correlated with the extent of MSC hepatoprotective performance in the two models.

We wonder whether a single administration of hMSCs was able to protect the liver from inflammation in two representative models. In ALI mice, hMSCs significantly reduced the ALT and AST levels and the proinflammation gene expressions (Fig. 1, B and C), consistent with reported studies before (Shi et al., 2019). Whereas in CLF, although single hMSCs administration reduced ALT/AST levels, it showed limited efficacy against chronic hepatic and pulmonary fibrosis (Fig. 1, G and H; Fig. 2, B and C). Actually, it has been confirmed in previous reports that usually at least two repeated administrations of MSCs were required to attenuate liver fibrosis in CLF models (Ali et al., 2012; Luo et al., 2019). For example, the dosage regimen in one successful MSCs' treatment on decompensated liver cirrhosis required patients to receive MSCs transfusion once every 4 weeks three times (8 weeks in total) (Zhang et al., 2012).

The exposure of hMSCs in the liver of these two models was both significantly enhanced, but hMSCs had a greater increase in the AUC_{Liver} 0–72 hour in ALI than CLF (177% versus 96.2%). The AUC_{Liver} 0–72 hour of hMSCs also increased significantly in ALI lung (51.1%). However, in CLF mice, a surprisingly declined hMSCs exposure was noticed: the AUC_{Lung} 0–72 hour and C_{max} decreased by 60.7% and 57.5%, respectively (Table 2). The PK properties showed similar trends in the fluorescent detection and qPCR assays (Fig. 3 and Supplemental Fig. 2).

Therefore, the next question is why MSCs had opposite cell fates in the lung of ALI and CLF. It has been widely reported that MSCs possess a homing capacity. The inflammatory sites would release signals and attract transplanted MSCs into the injury sites (Leibacher and Henschler, 2016). In our CLF model, pulmonary pathology, like inflammation infiltration, alveolar fibrosis, and stale hemorrhage, were all observed (Fig. 2B). However, the accumulation of MSCs in the lung significantly decreased compared with the control (Fig. 3D). This phenomenon couldn't be explained by the cell homing theory.

**TABLE 2**

<table>
<thead>
<tr>
<th>Liver</th>
<th>T_{max} (h)</th>
<th>MRT (h)</th>
<th>t_{1/2} (h)</th>
<th>C_{max} (FU × 10^5)</th>
<th>AUC_{0–72 h} (FU × h × 10^5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hMSCs</td>
<td>1</td>
<td>16.8 ± 0.7</td>
<td>20.0 ± 0.5</td>
<td>160.8 ± 18.8</td>
<td>2263.0 ± 89.6</td>
</tr>
<tr>
<td>+ fibrosis</td>
<td>1</td>
<td>25.6 ± 2.1***</td>
<td>51.8 ± 21.0*</td>
<td>237.0 ± 22.4***</td>
<td>4440.0 ± 337.7***</td>
</tr>
<tr>
<td>Lung</td>
<td>2.8 ± 3.5</td>
<td>25.8 ± 2.0</td>
<td>36.7 ± 12.4</td>
<td>495.8 ± 151.0</td>
<td>16991.0 ± 2068.0</td>
</tr>
<tr>
<td>hMSCs</td>
<td>2.4 ± 3.1</td>
<td>27.9 ± 4.3</td>
<td>68.4 ± 52.3</td>
<td>210.8 ± 93.2**</td>
<td>6680.0 ± 669.1***</td>
</tr>
</tbody>
</table>

*P < 0.05, **P < 0.01, ***P < 0.001, versus hMSCs.
NK cells are widely present in most mammal tissues, including lung, liver, spleen, and peripheral blood (Bjorkstrom et al., 2016; Cong and Wei, 2019). NK cells were reported to have critical roles in lysing hMSCs (Spaggiari et al., 2006). For exogenous MSCs, the low MHC-I expression and activating NK cell receptor ligands, like Poliovirus Receptor and MHC class I polypeptide-related sequence A, render it a susceptible target for NK cell-mediated lysis (Ej Reinders, 2014). The NK cell percentage in the lung of CLF animals increased 2–5 times compared with the control (Fig. 4D), which corresponded to the decreased hMSC cell exposure in the lung (Fig. 3D). On the contrary, in ALI animals, the percentage of NK cells was reduced in the lung (Fig. 4B), whereas hMSCs exposure increased (Fig. 3C). Interestingly, in the ALI experiment, there was no significant difference in the percentage of NK cells between animals with or without CCl4 induction at the beginning of MSC administration (1 hour), which was consistent with the fact that MSCs concentration did not change immediately after administration in ALI (Figs. 3A and 4C).

The decrease of NK cells in ALI animals was consistent with the previous report (Liu et al., 2019). Whereas to our knowledge, the increase of NK cells in the lung of CLF animals has never been reported before. It is reasonable to speculate that the activation of NK cells was responsible for the accelerated elimination of MSCs in CLF mice lung. In the following study, NK cells were depleted with antiasialo GM1 antibody. As expected, it brought a significantly greater accumulation in the lung and liver, which provided direct evidence for NK cell-mediated hMSC lysis (Fig. 5). The coculture systems also showed that hMSC were susceptible to the cytotoxicity of NK cells (Supplemental Fig. 4B).

In general, MSCs in the lung might be more susceptible to NK cells than in the liver. It was reported that in mice, lung NK cells account for about 10% of the lymphocytes, which was much higher than the percentages in other tissues, including liver (<2%) (Gregoire et al., 2007). Among them, the most mature and cytotoxic phenotype is CD27+ CD11b+ NK cells, which are found at a higher frequency in the lung NK cells (>70%) than those in the liver (<30%) (Wang et al., 2012). It is reasonable to speculate that the total injected MSC amounts in lung of CLF animals decreased remarkably because of the activation of NK cells, since nearly 90% of transplanted MSCs accumulated in the lung (Han et al., 2021).

Our finding has novel clinic meanings as well. Firstly, the clinic dosage needs adjustment based on the NK cell activities in patients instead of simply adopting the dosage scaled up from preclinical studies or used in healthy volunteers. Besides, in many liver cirrhosis clinic trials, patients have to receive repeated MSCs injections (Shi et al., 2012; Miryounesi et al., 2013; Chen et al., 2014; Jang et al., 2014; Liao et al., 2020). Our results supplied an alternative rationale for why hMSC may not work in the clinic: the accelerated clearance of hMSC.
in chronic liver fibrotic situations. The relationship between the PK variability, MSC efficacy, immune responses, and liver disease severity was linked in our study for the first time.

In this study, mouse adipose tissue-derived MSCs were employed to investigate if there is any species difference regarding the elimination pattern for MSCs under diseases compared with hMSCs. Higher mMSCs amounts and lower NK cell activities were found in the ALI mice, suggesting a similar kinetic pattern shared by human and mouse MSCs derived from different tissues (Fig. 6). These results suggested that it might be feasible to translate our preclinical findings into clinical studies but needs confirmation with more patient data. Our previous work suggested mMSC PK patterns are very close to hMSCs in healthy mice (Han et al., 2021). Considering the similar behavior of mMSC and hMSC in ALI, it is reasonable to speculate that PK patterns of mMSCs in the CLF model are close to hMSCs as well. Anyway, the speculation needs to be validated in future work, especially in the clinic.

There were also some limitations of the present study. For example, the pharmacokinetic pattern of MSCs and the participation of NK cells-mediated elimination needs to be further explored in other disease models. It is necessary to estimate the contribution of other immune cells as well. The fluorescent intensity of hMSCs in lung showed some fluctuations in the ALI experiment (Fig. 3C). The phenomenon might be
attributed to machine distraction, as such increase was not observed in the parallel qPCR studies (Supplemental Fig. 2B). Anyway, this discrepancy will not change the conclusion of that study. Besides, we noticed the discrepancy between the gene and protein expression of α-smn (Fig. 1, G and J; Fig. 2C), one important fibrosis marker. This phenomenon was found in another report (Park et al., 2009) and our in-house data, but the potential explanation remains to be further explored.

In conclusion, this study revealed the differences between the efficacy of MSCs in ALI and CLF, which could partly explain by the divergent NK functions. To the best of our knowledge, it is the first time investigating the PK of MSCs under liver diseases. The distinct fates and efficacies of MSCs in acute liver injury or chronic fibrosis mice led to a comprehensive understanding of cell disposition and elimination. Our data suggested that the NK cell-associated MSCs clearance in lung instead of the liver could be critical to MSC’s efficacy. Future studies will be warranted on these interesting questions to advance the application of MSCs in the clinic.

Acknowledgment

We thank Hexaell Biotech (Shanghai, China) for their support in providing us the human umbilical cord-derived mesenchymal stem cells.

Authorship Contributions

Participated in research design: C.H. Ma, Han, Tang, R. Huang, W. Huang, Pan.

Conducted experiments: C.H. Ma, Han, J. Wu, Deng, H. C. Ma.

Performed data analysis: C.H. Ma, Han, J. Wu, Z. Wu.

Wrote or contributed to the writing of the manuscript: C.H. Ma, Pan.

Reference


Creane M, Howard L, O’Riordan T, Shi X, Liu J, Chen D, Zhu M, Yu J, Xie J, Han Z, Zhang N, Jiang Q, Ma C, Huang R, et al. (2021) Dexamethasone (Fig. 1, G and J; Fig. 2C), one important fibrosis marker. This phenomenon was found in another report (Park et al., 2009) and our in-house data, but the potential explanation remains to be further explored.

In conclusion, this study revealed the differences between the efficacy of MSCs in ALI and CLF, which could partly explain by the divergent NK functions. To the best of our knowledge, it is the first time investigating the PK of MSCs under liver diseases. The distinct fates and efficacies of MSCs in acute liver injury or chronic fibrosis mice led to a comprehensive understanding of cell disposition and elimination. Our data suggested that the NK cell-associated MSCs clearance in lung instead of the liver could be critical to MSC’s efficacy. Future studies will be warranted on these interesting questions to advance the application of MSCs in the clinic.

Acknowledgment

We thank Hexaell Biotech (Shanghai, China) for their support in providing us the human umbilical cord-derived mesenchymal stem cells.

Authorship Contributions

Participated in research design: C.H. Ma, Han, Tang, R. Huang, W. Huang, Pan.

Conducted experiments: C.H. Ma, Han, J. Wu, Deng, H. C. Ma.

Performed data analysis: C.H. Ma, Han, J. Wu, Z. Wu.

Wrote or contributed to the writing of the manuscript: C.H. Ma, Pan.

Reference


Creane M, Howard L, O’Riordan T, Shi X, Liu J, Chen D, Zhu M, Yu J, Xie J, Han Z, Zhang N, Jiang Q, Ma C, Huang R, et al. (2021) Dexamethasone (Fig. 1, G and J; Fig. 2C), one important fibrosis marker. This phenomenon was found in another report (Park et al., 2009) and our in-house data, but the potential explanation remains to be further explored.

In conclusion, this study revealed the differences between the efficacy of MSCs in ALI and CLF, which could partly explain by the divergent NK functions. To the best of our knowledge, it is the first time investigating the PK of MSCs under liver diseases. The distinct fates and efficacies of MSCs in acute liver injury or chronic fibrosis mice led to a comprehensive understanding of cell disposition and elimination. Our data suggested that the NK cell-associated MSCs clearance in lung instead of the liver could be critical to MSC’s efficacy. Future studies will be warranted on these interesting questions to advance the application of MSCs in the clinic.

Acknowledgment

We thank Hexaell Biotech (Shanghai, China) for their support in providing us the human umbilical cord-derived mesenchymal stem cells.

Authorship Contributions

Participated in research design: C.H. Ma, Han, Tang, R. Huang, W. Huang, Pan.

Conducted experiments: C.H. Ma, Han, J. Wu, Deng, H. C. Ma.

Performed data analysis: C.H. Ma, Han, J. Wu, Z. Wu.

Wrote or contributed to the writing of the manuscript: C.H. Ma, Pan.

Reference


Creane M, Howard L, O’Riordan T, Shi X, Liu J, Chen D, Zhu M, Yu J, Xie J, Han Z, Zhang N, Jiang Q, Ma C, Huang R, et al. (2021) Dexamethasone (Fig. 1, G and J; Fig. 2C), one important fibrosis marker. This phenomenon was found in another report (Park et al., 2009) and our in-house data, but the potential explanation remains to be further explored.

In conclusion, this study revealed the differences between the efficacy of MSCs in ALI and CLF, which could partly explain by the divergent NK functions. To the best of our knowledge, it is the first time investigating the PK of MSCs under liver diseases. The distinct fates and efficacies of MSCs in acute liver injury or chronic fibrosis mice led to a comprehensive understanding of cell disposition and elimination. Our data suggested that the NK cell-associated MSCs clearance in lung instead of the liver could be critical to MSC’s efficacy. Future studies will be warranted on these interesting questions to advance the application of MSCs in the clinic.

Acknowledgment

We thank Hexaell Biotech (Shanghai, China) for their support in providing us the human umbilical cord-derived mesenchymal stem cells.

Authorship Contributions

Participated in research design: C.H. Ma, Han, Tang, R. Huang, W. Huang, Pan.

Conducted experiments: C.H. Ma, Han, J. Wu, Deng, H. C. Ma.

Performed data analysis: C.H. Ma, Han, J. Wu, Z. Wu.

Wrote or contributed to the writing of the manuscript: C.H. Ma, Pan.
SUPPLEMENTAL MATERIALS

MSCs cell fates in murine acute liver injury and chronic liver fibrosis induced by carbon tetrachloride

Chenhui Ma\textsuperscript{1,2}, Li Han\textsuperscript{1,2}, Jiajun Wu\textsuperscript{1,2}, Feng Tang\textsuperscript{1,2}, Qiangqiang Deng\textsuperscript{1}, Ting He\textsuperscript{1,3}, Zhitao Wu\textsuperscript{1}, Chen Ma\textsuperscript{1,2}, Wei Huang\textsuperscript{1,2*}, Ruimin Huang\textsuperscript{1,2*}, and Guoyu Pan\textsuperscript{1,2*}

\textsuperscript{1} Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

\textsuperscript{2} University of Chinese Academy of Sciences, Beijing 100049, China

\textsuperscript{3} School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China
**Supplementary Material**

**Supplementary Table**

Table S1. Primer sequences

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>hAlu</td>
<td>forward CTTCAGTGAGCCGAGATT</td>
</tr>
<tr>
<td></td>
<td>reverse GAGACGGAGTCTGCTGTC</td>
</tr>
<tr>
<td>β-actin (m, h)</td>
<td>forward TCAGCAATGCCTGGGTACAT</td>
</tr>
<tr>
<td></td>
<td>reverse ATCACTATGGCAACGAGCG</td>
</tr>
<tr>
<td>mCol1a1</td>
<td>forward CAATGGCAGGGCTGTGGCG</td>
</tr>
<tr>
<td></td>
<td>reverse AGCACTCGCCCTCCGTCTT</td>
</tr>
<tr>
<td>mCol3a1</td>
<td>forward GAGGAATGGGTGCTATCCG</td>
</tr>
<tr>
<td></td>
<td>reverse TGCGGCATCAAGCCCTCT</td>
</tr>
<tr>
<td>mTNF-α</td>
<td>forward CTGTAGCCCACGTGTAGC</td>
</tr>
<tr>
<td></td>
<td>reverse TTGAGATCCATGGCGTTG</td>
</tr>
<tr>
<td>mIL-1β</td>
<td>forward ATGCCACCTTTTGACAGTATG</td>
</tr>
<tr>
<td></td>
<td>reverse AGCTTCTCCACAGCCACAAT</td>
</tr>
<tr>
<td>mGAPDH</td>
<td>forward AGGTCGGTTGAAACCGATTTG</td>
</tr>
<tr>
<td></td>
<td>reverse GGGTGCGTATGGCAACA</td>
</tr>
</tbody>
</table>
Supplemental Figure 1: Representative fluorescent image of cy5-labeled hMSC in organs. (A) Representative fluorescent images in organs (heart, liver, spleen, lung, kidney) in ALI. (B) Representative fluorescent images in CLF.
Supplemental Figure 2: The concentration-time curves of hMSCs in lung and liver by qPCR. (A-B) The hMSCs concentration-time curves in lung and liver in acute liver injury. Data were showed as the mean ± SD, n = 5 (*P<0.05, **P<0.01, hMSCs + ALI vs. hMSCs). (C-D) The hMSCs concentration-time curves in lung and liver in advanced fibrosis. Data were showed as the mean ± SD, n = 5 (*P<0.05, **P<0.01, hMSCs + fibrosis vs. hMSCs). (E-F) The hMSCs concentration-time curves in lung and liver in NK-depleted mice. Data were showed as the mean ± SD, n = 4 (**P<0.01, ***P<0.001, hMSCs + NK-depleted vs. hMSCs).
Supplemental Figure 3: Immunofluorescence staining of NK cells in the lung and liver. Representative immunofluorescence staining of CD107a (Green) and Nkp46 (Red) in the lung (A) and liver (B) in the ALI mice. Representative immunofluorescence staining of NK cells in the lung (C) and liver (D) in the CLF mice. Scale bar: 100 μm.
Supplemental Figure 4: NK cells mediate the lysis of MSCs. (A) Frequency of Nkp46+CD49b cells in spleen were quantified after the depletion of splenic NK cells by anti-Asialo GM1 antibody. Data were represented as the mean ± SD, n = 4 (‘P< 0.05, vs Con; #P< 0.05, ##P< 0.01, vs hMSCs; ns, not significant). (B) IL-2-activated NK cells lyse MSCs. NK92 cells incubated with 0, 100, 300, 500U/ml IL-2 supplemented medium for 3 days could lead to significant cytolytic activity (E/T ratio = 30:1). The results were showed as the mean ± SD, n = 3 (**P< 0.001, vs. the hMSCs + NK92(0 U/ml)). Pos, Positive Control group.